Cutaneous adverse drug reaction after apomorphine infusion, possibly caused by a systemic type IV hypersensitivity reaction to sodium metabisulfite: Report of 2 cases

Borgemeester, Robbert W K; Laar, Teus van; Schuttelaar, Marie L A

doi:10.1111/cod.13058

Cited by 13 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Borgemeester et al 9 reported two cases of morbilliform rash probably caused by a systemic type IV hypersensitivity reaction to sodium metabisulphite present in the APO solution, which we could not confirm in our patient. Nevertheless, systemic corticosteroids used until 2 days before patch testing may be responsible for false negative results.…”

contrasting

confidence: 72%

See 1 more Smart Citation

Cutaneous adverse drug reaction after continuous subcutaneous apomorphine infusion

Calvão

Cardoso

Moreira

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

breastfeeding period was uncomplicated during the next 4 months of observational period. The European Medicines Agency (EMA) reported 2017 data from one phase-2b and three phase-3 studies including 2500 AE patients, whereby 23 pregnancies of female patients treated with dupilumab resulted in deliveries of eight healthy babies (1 twin birth), two induced abortions and six spontaneous abortions. In two of these six cases, patients had at least one risk factor for abortion (i.e. elevated parathyroid hormone, clotting disorders and history of infertility). Five pregnancies were still ongoing at that point, and three pregnancies were lost to follow-up. 8 In the EMA assessment report for the indication expansion of dupilumab in treatment for asthma published in 2019, nineteen pregnancies were reported from one phase-2b and two phase-3 studies. Pregnancies resulted in eight healthy babies (one twin birth), one baby with Turner's syndrome, five spontaneous and three induced abortions. Of the five spontaneous abortions, three patients had at least one risk factor for abortion (i.e. clotting disorders, infertility treatments, advanced age and twin pregnancy). Three pregnancies were still ongoing. The spontaneous abortion rate did not exceed the general spontaneous abortion rate. 9 Accordingly, until today, neither clinical nor experimental data nor theoretical considerations point to dupilumab's teratogenic capacity. However, the ETAD advises that other systemic drugs should be used instead of dupilumab in pregnant women with AE until more experience is available. 6 Our case supports the idea that dupilumab may be used after careful risk-benefit assessment in pregnancy and lactation if all other therapies have failed. There was no funding to support this work.

show abstract

contrasting

confidence: 72%

“…Hypersensitivity reactions to sodium metabisulphite are well known, with contact allergy diagnosed in 3.12% of consecutively patch-tested patients. 9 Inversely, allergic contact dermatitis to APO was first described in 1977, 10 and since then only a few cases have been reported, 1 with no cross-reactions with morphine, as in the present case.…”

supporting

confidence: 46%

Cutaneous adverse drug reaction after continuous subcutaneous apomorphine infusion

Calvão

Cardoso

Moreira

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Common published adverse events of CSAI in major case series and case reports are listed in Table 4 and Table S1. 18,22,[24][25][26]29,[52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71] In an audit on reasons for discontinuing therapy of 107 patients over 10 years, Tyne et al 18 reported that therapy was discontinued in 16% of patients (with some opting for intermittent injections, and 10 going on to DBS). Although nine patients died during the audit periods, none of the deaths were attributed to CSAI.…”

Section: Causes For Discontinuation and Adverse Events Of Csaimentioning

confidence: 99%

Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review

Kukkle

Garg

Merello

2023

Movement Disord Clin Pract

View full text Add to dashboard Cite

BackgroundContinuous subcutaneous apomorphine infusion (CSAI) is one of the advanced therapies for Parkinson's disease (PD).MethodsA systematic review of all published articles in English on CSAI for PD till January 30, 2022 was conducted.ResultsA total of 82 articles met the search criteria. Publications included retrospective or prospective open‐label observational studies, with a limited number of randomized control trials (RCT). Publications were highly heterogeneous and focused on different aspects of CSAI and included clinical audits, effects on cognition/behavior, axial symptoms, nocturnal issues, adverse events/reasons for discontinuation and comparison with other continuous dopaminergic therapies. CSAI was used in patients who presented severe motor fluctuations not resolved by oral therapy, poor candidates for deep brain stimulation (DBS) due to cognitive/behavioral issues or in those with DBS weaning effect. Recent studies have also shown that CSAI was useful for nocturnal usage in advanced PD, in addition to daytime utilization. Adverse effects were common and include skin lesions, sedation and nausea. Pump management difficulties and patient decisions were common reasons for therapy dropout, predominantly during the initial stages of the CSAI.ConclusionThere is consistent agreement on the benefits of CSAI in reducing OFF periods and improving ON periods without troublesome dyskinesia and specific motor and non‐motor symptoms. Although there is a paucity of RCTs, current data from almost 30 years of use suggests CSAI to be beneficial in advanced cases of PD.

show abstract

“…Sulfites in gloves are a newly recognized source of exposure 50 . Systemic contact dermatitis has been described following oral, rectal, and/or parenteral exposure 26,29‐31,45 …”

Section: Introductionmentioning

confidence: 99%

Patch testing with sodium disulfite: North American Contact Dermatitis Group experience, 2017 to 2018

et al. 2021

View full text Add to dashboard Cite

Background Sodium disulfite (SD), also known as sodium metabisulfite, is an increasingly recognized cause of allergic contact dermatitis. Objectives The objective of this work was to characterize individuals with positive patch test reactions to SD as well as analyse reaction strength, clinical relevance, and sources. Methods This is a retrospective analysis of patients patch tested with SD (1% petrolatum) by the North American Contact Dermatitis Group (NACDG), 2017 to 2018. Results Of 4885 patients patch tested with SD, 132 (2.7%) had a positive reaction. Common primary anatomic sites of dermatitis were face (28.8%), hands (20.5%), and a scattered/generalized distribution (13.6%). Compared with SD‐negative patients, SD‐positive patients were more likely male (odds ratio 2.81, 95% confidence interval 1.98‐4.00) and/or over 40 years (odds ratio 1.95, 95% confidence interval 1.30‐2.94). Reactions were most commonly + (50.4%) or ++ (34.1%); 65.2% were considered currently relevant. About 15.2% were definitively confirmed in sources, commonly personal care products (18.9%, especially hair dye), and drugs/medications/alcoholic beverages (9.1%). Only 2.3% of positive reactions were linked to occupation. Conclusions Positive reactions to SD occurred in 2.7% of tested patients. Reactions were often clinically relevant and linked to personal care products and drugs/medications/alcoholic beverages.

show abstract

Cutaneous adverse drug reaction after apomorphine infusion, possibly caused by a systemic type IV hypersensitivity reaction to sodium metabisulfite: Report of 2 cases

Cited by 13 publications

References 12 publications

Cutaneous adverse drug reaction after continuous subcutaneous apomorphine infusion

Cutaneous adverse drug reaction after continuous subcutaneous apomorphine infusion

Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review

Patch testing with sodium disulfite: North American Contact Dermatitis Group experience, 2017 to 2018

Contact Info

Product

Resources

About